

Mouse PD-L2/B7-DC Alexa Fluor® 750-conjugated Antibody

Monoclonal Rat IgG_{2A} Clone # 168633

Catalog Number: FAB1022S

| DESCRIPTION | | | |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Species Reactivity | Mouse | | |
| Specificity | Detects mouse PD-L2/B7-DC in direct ELISAs and Western blots. In direct ELISAs and Western blots, 100% cross-reactivity with recombinant human (rh) PD-L2 is observed and no cross-reactivity with rhB7-1, recombinant mouse (rm) B7-1, rmB7-2, rmB7-H1, rmB7-H2, rmB7-H3, or rmB7-H4 is observed. | | |
| Source | Monoclonal Rat IgG _{2A} Clone # 168633 | | |
| Purification | Protein A or G purified from hybridoma culture supernatant | | |
| Immunogen | Mouse myeloma cell line NS0-derived recombinant mouse PD-L2/B7-DC Met1-Arg219 Accession # Q9WUL5 | | |
| Conjugate | Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm | | |
| Formulation | Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details. | | |
| | *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Shee (SDS) for additional information and handling instructions. | | |

| APPLICATIONS | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|----------------------------------------------------------------------------|--|--|
| Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website. | | | | |
| | Recommended Concentration | Sample | | |
| Flow Cytometry | 0.25-1 μg/10 ⁶ cells | HEK293 human embryonic kidney cell line transfected with mouse PD-L2/B7-DC | | |
| | | | | |

| PREPARATION AND STORAGE | | | |
|-------------------------|-------------------------------------------------------------------------------------------------------------------|--|--|
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. | | |
| Stability & Storage | Protect from light. Do not freeze. ■ 12 months from date of receipt, 2 to 8 °C as supplied. | | |

BACKGROUND

Mouse Programmed Death Ligand 2 (PD-L2), also named B7DC and butyrophilin-like protein, is a member of the B7 family of proteins that provide signals for regulating T-cell activation and tolerance (1-4). Other family members include B7-1, B7-2, B7-H2, PD-L1 (B7-H1), and B7-H3. B7 proteins are immunoglobulin (Ig) superfamily members with extracellular Ig-V-like and Ig-C-like domains and short cytoplasmic domains. Among the family members, they share from 20-40% amino acid (aa) sequence identity. The cloned mouse PD-L2 cDNA encodes a 247 aa type I membrane precursor protein with a putative 20 aa signal peptide, a 199 aa extracellular region containing one V-like and one C-like Ig domain, a 23 aa transmembrane region, and only a 5 aa cytoplasmic domain. The extracellular domains of mouse and human PD-L2 share approximately 72% aa sequence identity. PD-L2 is one of two ligands for programmed death-1 (PD-1), a member of the CD28 family of immunoreceptors. The other identified ligand is PD-L1. Mouse PD-L1 and PD-L2 share approximately 34% aa sequence identity and have similar functions. PD-L2 is constitutively expressed in lymphoid and non-lymphoid organs (1-4). The expression of PD-L2 is detected on dendritic cells, thymic epithelial cells and IFN-y treated monocytes. PD-L2 expression is also upregulated in a variety of tumor cell lines. On previously activated T cells, PD-L2 interaction with PD-1 inhibits TCR-mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. In contrast, a co-stimulatory function for the PD-1 ligands on resting T cells has also been reported.

References:

- Latchman, Y. et al. (2001) Nature Immun. 2:261. 1.
- Tseng, B.S-Y. et al. (2001) J. Exp. Med. 193:839.
- Sharpe, A.H. and G.J. Freeman (2002) Nat. Rev. Immunol. 2:116.
- Coyle, A. and J. Gutierrez-Ramos (2001) Nat. Immunol. 2:203

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

Rev. 2/6/2018 Page 1 of 1

